[HTML][HTML] Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
OJ McElvaney, E O'Connor, NL McEvoy… - Journal of Cystic …, 2021 - Elsevier
OJ McElvaney, E O'Connor, NL McEvoy, DD Fraughan, J Clarke, OF McElvaney…
Journal of Cystic Fibrosis, 2021•ElsevierBackground The clinical course of severe COVID-19 in cystic fibrosis (CF) is incompletely
understood. We describe the use of alpha-1 antitrypsin (AAT) as a salvage therapy in a
critically unwell patient with CF (PWCF) who developed COVID-19 while awaiting lung
transplantation. Methods IV AAT was administered at 120 mg/kg/week for 4 consecutive
weeks. Levels of interleukin (IL)-1β, IL-6, IL-8, and soluble TNF receptor 1 (sTNFR1) were
assessed at regular intervals in plasma, with IL-1β, IL-6, IL-8 and neutrophil elastase (NE) …
understood. We describe the use of alpha-1 antitrypsin (AAT) as a salvage therapy in a
critically unwell patient with CF (PWCF) who developed COVID-19 while awaiting lung
transplantation. Methods IV AAT was administered at 120 mg/kg/week for 4 consecutive
weeks. Levels of interleukin (IL)-1β, IL-6, IL-8, and soluble TNF receptor 1 (sTNFR1) were
assessed at regular intervals in plasma, with IL-1β, IL-6, IL-8 and neutrophil elastase (NE) …
Background
The clinical course of severe COVID-19 in cystic fibrosis (CF) is incompletely understood. We describe the use of alpha-1 antitrypsin (AAT) as a salvage therapy in a critically unwell patient with CF (PWCF) who developed COVID-19 while awaiting lung transplantation.
Methods
IV AAT was administered at 120 mg/kg/week for 4 consecutive weeks. Levels of interleukin (IL)-1β, IL-6, IL-8, and soluble TNF receptor 1 (sTNFR1) were assessed at regular intervals in plasma, with IL-1β, IL-6, IL-8 and neutrophil elastase (NE) activity measured in airway secretions. Levels were compared to baseline and historic severe exacerbation measurements.
Results
Systemic and airway inflammatory markers were increased compared to both prior exacerbation and baseline levels, in particular IL-6, IL-1β and NE activity. Following each AAT dose, rapid decreases in each inflammatory parameter were observed. These were matched by marked clinical and radiographic improvement.
Conclusions
The results support further investigation of AAT as a COVID-19 therapeutic, and re-exploration of its use in CF.
Elsevier
